Ddu News – Page 9 – media

FDA approves Masimo’s Tiny Breathing Sensor for Paediatric patients in U.S.

The RAS-45 acoustic respiration sensor, developed by Masimo, to function along with the Rainbow Acoustic Monitoring (RAM), was approved by the FDA for use in neonates and infant patients. A minimum weight of 22pounds/10 kgs of the baby was required earlier to be eligible for use of RAM sensors. This requirement is no longer necessary for the new sanction that enables a convenient monitoring of the rate of respiration in very young pediatric patients. This is possible because the maximum respiration rate in the sensor has been raised to 120 breaths per minute with an excellent precision between +/- breath every minute. The sensor can be stuck on to the child and it is fitted with a microphone mimicking device that spots respiration sounds from other background sounds. Its clarity enables pediatricians to listen to the breathing of the infant as if he/she is listening via a stethoscope. The sensor ...
- Source: drugdu
- 99
- September 12, 2018
Brain Atrophy slowed by Multiple Sclerosis Drug

Ibudilast retarded brain atrophy in 255 advancing multiple scleroses (MS) patients more than a placebo in a National Institute of Health’s (NIH) National Institute of Neurological Disorders and Stroke (NINDS) funded the brain imaging clinical trial. 28 clinical locations were studied for 96 weeks to evaluate the decline in brain atrophy progress. MRI scans were done on the patients’ brains half-yearly. Varied analysis techniques were used as scales to measure the variations in brain alterations seen in the MRI films among the two groups. Brain atrophy was observed in both the groups but the ibudilast group demonstrated the slower rate of shrinkage of the brain. The brain shrunk by 2.5ml more over two years in the group on placebo. NINDS director Walter Koroshetz said, “These findings provide a glimmer of hope for people with a form of multiple sclerosis that causes long-term disability but does not have many treatment options.” ...
- Source: drugdu
- 76
- September 12, 2018
Hospital stay reduced to half with Danish endocarditis plan

A Danish, multicenter, randomized POET trial revealed that after declared clinically stable on taking intravenous antibiotics in a hospital for one to two weeks, left-sided endocarditis patients could be sent home with a prescription of antibiotics to be taken orally to complete the rest of the treatment. “Shifting to oral antibiotic treatment in stabilized patients with endocarditis was as effective and safe as continued intravenous antibiotic treatment and was given during half the antibiotic treatment period. These novel findings may have a significant impact on future clinical practice for the management of patients who are stable,” Henning Bundgård, MD, said at the annual congress of the European Society of Cardiology. Guiding principles from the ESC and American Heart Association/American College of Cardiology suggest 6 weeks of intravenous antibiotics for the management of infective endocarditis. This reduces the stay in the hospital to half resulting in lowering of the expenses borne by ...
- Source: drugdu
- 81
- September 11, 2018
Retention in de-addiction therapy increased on administration of medicines.

Medications like buprenorphine, naltrexone, or methadone when added to treatment of opioid use disorder (OUD) youths, resulted in longer adherence to in-care regimen. However, very few receive the medicines, reveals a retrospective cohort study. The study on 4,837 OUD youths between the age 13-22 years including 2,752 females observed that only 1 out of 4 youths and 1 out of 21 adolescents received medication, as reported by Scott E. Hadland, MD, MPH, MS, of Grayken Center for Addiction and Department of Pediatrics, Boston Medical Center, and coinvestigators. The results brought greater attention to the need for better management of OUD in young adults and increase their adherence to treatment, noted Dr. Hadland and co-authors in JAMA Pediatrics. “As deaths from overdose increase among U.S. youths, it is vital that clinicians, researchers, and policy makers ensure that access to evidence-based OUD medications for young people remains a national priority,” they said. The ...
- Source: drugdu
- 72
- September 11, 2018
Crazy cat lady syndrome might also treat cancer

We might have come across many people who are usually obsessed with cats. But at times, this obsession can turn into madness. Where does this madness arise from? There is a research link between the cat parasite named Toxoplasma gondii and the psychiatric disorders like bipolar disorder and schizophrenia. House cats are considered as the primary hosts of Toxoplasma gondii. But according to a study published in Psychological Medicine in 2017, it was reported that just having the cats doesn’t increase the risk of psychosis. It’s the cat parasite that causes psychosis. Later, a research team from Dartmouth College’s Geisel School of Medicine NH, were trying to find the parasite’s immune power against cancer tumors, with the ultimate goal of making a cancer vaccine. Researchers have known that T. gondii infection strongly induces a Th1 immune response, which can increase the cancer survival rates. David J. Bzik, PhD, the lead ...
- Source: drugdu
- 79
- September 11, 2018
Wearable chronic pain reliever app – Quell 2.0

Nearly millions of people throughout the world are living with chronic pain in one form or the other. With the rise of opioids in the epidemic level, there arises a rise in search for new treatment measures. The wearables company named NeuroMetrix had redesigned their device named Quell for an easier and convenient utilization. The modified Quell 2.0 app has taken the FDA approved nerve stimulation technology to the next level, which is supposed to be the latest breakthrough for chronic pain treatment. The Quell 2.0 device is smarter, 50% smaller and 20% more powerful. The new Quell 2.0 app is available online at www.QuellRelief.com. Quell 2.0 app is integrated with a neurostimulation microchip which includes all the features of Quell device. It easily adapts to changes in body position and automatically starts the therapy in switch-on mode. This app is user-friendly with a varied automation feature like start and stop, ...
- Source: drugdu
- 24
- September 11, 2018
Vision test via voice recognition

Opternative had developed the world’s first web-based vision test via voice activation. The users can renew their prescription online using their smartphones, even if their prescription got changed. This web-based technology totally relies upon voice recognition software belonging to Microsoft, Google and IBM Watson for a safe and easy voice guided vision test. This technology understands the voice of patients and proceed them through the online vision test for the continuous medical conversation, which overall takes less than 15 minutes. The existing solution of Opternative includes both smartphone and computer; whereas, this present technology uses only the smartphone. The company was founded in 2012, which is specialized in performing vision test from anywhere at any time and get an accurate reliable prescription via online. They have created online modernized digital eye care technologies, which include detection of refractive errors and ocular health profile by the certified eye-specialists, thereby promoting enhanced user ...
- Source: drugdu
- 26
- September 11, 2018
Dyspareunia can spoil your sexual life – Act immediately!

A type of physical discomfort where the pain occurs during sexual intercourse is termed as dyspareunia. Even after intercourse, this throbbing pain may last for hours. Pain might occur due to lack of lubrication or infection in genital area. Other emotional causes like stress or history of sexual abuse may also play a major role. Females are more affected compared to males. Sometimes the condition of dyspareunia is often mistaken for lack of interest in the relationship which might cause emotional distress and greater misunderstandings. It’s high time not to feel shy and the need of the hour is to follow five treatment options listed below, to improve sexual life and emotional intimacy. Antibiotic treatment: The major cause of dyspareunia in women is pelvic inflammatory diseases (PID) which is caused due to microbial infections. Hence, the administration of proper antibiotic treatment can cure PID and dyspareunia. Psychological therapy: Psychological counseling ...
- Source: drugdu
- 59
- September 11, 2018
Drawback in PSMA PET imaging technique observed by researchers.

A study published in the September issue of The Journal of Nuclear Medicine remarked that it noticed a huge drawback in the Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging technique and warned doctors who use only PSMA PET for diagnosis to be vigilant for faulty diagnosis. “It is important that nuclear medicine physicians be aware of this pitfall, as the interpretation of PSMA PET scans may have a substantial impact on therapy guidance,” said Christoph Rischpler, MD, in the department of nuclear medicine at the Technical University of Munich in Germany. For detecting prostate cancer staging and metastases in imaging, PSMA proves to be a very efficient target as it is an extremely easy-to-read enzyme, helping better diagnosis and plotting of management protocol. Recent findings, however, show that PSMA elevates in response to some benign tissue as well, duplicating findings of lymph node metastases. This could lead to ...
- Source: drugdu
- 60
- September 11, 2018
New drug formulation for opioid addiction approved by FDA.

Cassipa, a Teva Phaarmaceuticals manufactured sublingual film containing naloxone and buprenorphine in new dosage amounts, receives FDA approval on the 7th of September as a continuing therapy for opioid addiction. In a press release, the FDA announced that the buprenorphine and naloxone sublingual film, formulated in a 16 mg/4 mg dose for Cassipa, is sanctioned not only in its brand version but also in its generic edition. The two drugs in different strength combinations are also approved by the FDA. A set management protocol including psychotherapy and counseling should comprise of Cassipa post the patient is administered and stabilized with a step-ladder buprenorphine 16 mg dose of another brand. Drug Addiction Treatment Act (DATA) certified professionals only can prescribe these drugs. “There’s an urgent need to ensure access to, and wider use and understanding of, medication-assisted treatment for opioid use disorder … the FDA recently described a streamlined approach to ...
- Source: drugdu
- 75
- September 11, 2018

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

Exhibitions & Activitiesmore

Ddu to Attend CPhI in Shanghai Sharing Insights on International Marketing of the Medical Trade

June 19, 2018
IRANPHARMA EXPO 2018

June 14, 2018
Drugdu.com Launches Digital Marketing Strategy Solution for Pharmaceuticals and Medical Devices at CMEF Shanghai 2018

May 8, 2018
Ddu Attended CPhI North America Great Success with the “Internet + Cross-border medical trade” Marketing Model

May 3, 2018
Ddu’s International Medical Exhibition Attendance Delivering High Results.

April 9, 2018

Market Reportsmore

Best healthcare facilities

September 26, 2018
China’s Import and Export Market Report of Diabetes Drugs

May 4, 2018
China’s Import and Export Market Report of Vitamins

April 11, 2018
China’s Import and Export Market Report of Contraceptive Drugs

March 16, 2018
Ddu College — China’s Import and Export Report of Peptic Ulcer Drugs

January 25, 2018

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.